The role and significance of VEGFR2+ regulatory T cells in tumor immunity

Abstract

Panrong Zhu, Chenxi Hu, Kaiyuan Hui, Xiaodong Jiang Tumor Laboratory, Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu, China Abstract: Tumor development is closely related to angiogenesis, and VEGFR2 plays an important role in tumor angiogenesis. It is broadly expressed in the blood vessels, especially in the microvessels of tumor tissues. Furthermore, VEGFR2 is detected on the surface of the cell membrane in various immune cells, such as dendritic cells, macrophages, and regulatory T cells (Tregs). Tregs, which are one of the key negative regulatory factors in tumor immune microenvironments, show high-level expression of VEGFR2 which participates in the regulation of immunosuppressive function. VEGFR2+ Tregs play a potent suppressive role in the formation of immunosuppressive microenvironments. A large number of reports have proven the synergistic effects between targeted therapy for VEGFR2 and immunotherapy. The depression of VEGFR2 activity on T cells can significantly reduce the infiltration of Tregs into the tumor tissue. Targeted therapy for VEGFR2+ Tregs also provides a new choice for the clinical treatment of malignant solid tumors. In this paper, the role and significance of VEGFR2+ Tregs in tumor immunity in recent years are reviewed. Keywords: anti-angiogenesis, tumor immune escape, tumor microenvironment, antitumor immunity, regulatory T cell, VEGFR2

Keywords

• Anti-angiogenesis
• Tumor immune escape
• Tumor microenvironment
• Antitumor Immunity
• Regulatory T cell
• VEGFR2